Company profile: Circle Pharma
1.1 - Company Overview
Company description
- Provider of bioavailable macrocyclic peptide therapeutics targeting intracellular protein-protein interactions, supported by the MXMO platform that combines computational structure-based design and synthetic chemistry to create cell-permeable macrocycles. Offers cyclin A/B inhibitors for cancers with Retinoblastoma pathway mutations and other tumors, advancing precision oncology and therapeutics for 'undruggable' targets.
Products and services
- MXMOTM Platform: A structure-based platform combining computational design and synthetic chemistry to engineer cell-permeable, bioavailable macrocyclic peptides that target intracellular protein-protein interactions
- Macrocycle Therapeutics: Precision-oncology-focused therapeutics developing macrocyclic peptides to address 'undruggable' targets by targeting protein-protein interactions with bioavailability and cell permeability
- Cyclin A/B Inhibitors: Custom-engineered macrocyclic therapeutics that target cyclin proteins A and B to treat cancers with Retinoblastoma pathway mutations and additional tumor types
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Circle Pharma
MediWise
HQ: United Kingdom
Website
- Description: Provider of medical research and development, pioneering cutting-edge wireless devices for medical diagnostics and monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MediWise company profile →
Phoenix Biotechnology
HQ: United States
Website
- Description: Provider of research and development of therapeutic agents and treatment regimens for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phoenix Biotechnology company profile →
Dren Bio
HQ: United States
Website
- Description: Provider of protein engineering technologies for depleting cells, protein aggregates, and other disease-causing agents. Develops antibody therapeutics including DR-01, a fully human, nonfucosylated ADCC-inducing antibody for hematologic malignancies and autoimmune disorders, and a Targeted Myeloid Engager and Phagocytosis Platform with DR-0201 for B cell malignancies and DR-0202 for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dren Bio company profile →
PACT Pharma
HQ: United States
Website
- Description: Provider of personalized adoptive T cell therapies designed for the eradication of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PACT Pharma company profile →
Agios
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics focused on cancer metabolism, offering PYRUKYND (mitapivat), an approved therapy for adults with pyruvate kinase deficiency to treat hemolytic anemia; late-stage trials of mitapivat for thalassemia and sickle cell disease; AG-946, an early-stage PK activator; and patient access services including myAgios and a Global Managed Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agios company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Circle Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Circle Pharma
2.2 - Growth funds investing in similar companies to Circle Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Circle Pharma
4.2 - Public trading comparable groups for Circle Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →